Neurogene revealed it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $200 million. Neurogene is developing approaches and treatments which it hopes will address the limitations of conventional gene therapy in central nervous system disorders. According to […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!